Illumina, Inc. $ILMN Position Trimmed by AE Wealth Management LLC

AE Wealth Management LLC decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 29.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,337 shares of the life sciences company’s stock after selling 9,044 shares during the quarter. AE Wealth Management LLC’s holdings in Illumina were worth $2,026,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. WCM Investment Management LLC boosted its position in shares of Illumina by 5.9% during the 2nd quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock valued at $419,585,000 after acquiring an additional 247,460 shares in the last quarter. Loomis Sayles & Co. L P grew its stake in Illumina by 1.9% in the second quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock valued at $403,158,000 after purchasing an additional 78,317 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Illumina by 55.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after acquiring an additional 1,174,295 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Illumina by 0.7% in the second quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock valued at $272,921,000 after purchasing an additional 21,342 shares during the last quarter. Finally, Bank of America Corp DE increased its position in Illumina by 1.9% during the second quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock worth $184,222,000 after acquiring an additional 35,167 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the transaction, the insider directly owned 17,887 shares in the company, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.17% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Canaccord Genuity Group boosted their target price on shares of Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research note on Monday, January 26th. Stifel Nicolaus lifted their price target on shares of Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Zacks Research cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. Guggenheim increased their target price on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, Evercore ISI reissued an “outperform” rating and issued a $155.00 target price on shares of Illumina in a research report on Monday, January 5th. Six equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $127.18.

Illumina Trading Down 3.3%

ILMN stock opened at $144.81 on Monday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The firm’s 50-day moving average is $138.08 and its 200 day moving average is $115.16. The company has a market capitalization of $22.13 billion, a PE ratio of 32.47, a P/E/G ratio of 2.40 and a beta of 1.45. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $155.53.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The business’s quarterly revenue was up .4% on a year-over-year basis. During the same quarter last year, the firm earned $1.14 EPS. On average, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.